Treatment for all – help support DAA treatments for everyone with hep C.
Hepatitis NSW invites you to tell the PBAC why new pan-genotypic treatment, Epclusa, should be made available in Australia to treat people with hepatitis C.
New Direct Acting Anti-viral treatments were funded on the Pharmaceutical Benefits Scheme (PBS) from 1 March 2016. These treatments cure 95% of people in just 12 weeks with minimal side-effects, but interferon free treatment is still not available for genotypes 4, 5 and 6. Also complex treatment regimens for different genotypes may limit the capacity of GPs to treat everyone with hepatitis C.
The Pharmaceutical Benefits Advisory Committee (PBAC) is soon to consider whether the following new combination treatments for hep C should be made available on the PBS to people in Australia living with hep C.
Epclusa is a once-daily, single tablet combination containing two direct-acting antiviral (DAA) drugs, sofosbuvir and velpatasvir, that are active against hepatitis C genotypes 1, 2, 3, 4, 5 and 6. It simplifies treatment by potentially eliminating the need for genotype testing and is especially useful for people whose hep C may be resistant to previous treatments.
Harvoni, which was previously approved for treating genotype 1, is being considered for the treatment of patients with HCV genotypes 1 to 6 with decompensated cirrhosis, and for treatment-naïve patients with HCV genotype 3, in combination with ribavirin.
Technivie, which was previously approved as one part of the brand name Viekira Pak (approved for genotype 1), is being considered for the treatment of patients with genotype 4 chronic HCV infection, in combination with ribavirin.
Hepatitis NSW is asking community members and healthcare workers to make a submission to the PBAC in support of Epclusa, Harvoni and Technivie. Making treatment as simple as possible and accessible for everyone with hep C is an important part of helping to eliminate hep C in Australia.
We invite you to tell the PBAC why these new treatments are so important. You can have a direct impact on the eliminating the threat of hepatitis C by ensuring the first pan-genotypic new treatment is available in Australia.
Submissions close 5 October 2016, so time is tight. Please download the submission guide and follow the link to make an online submission.